Single Dose
Therapeutics
Vision
We envision a future where psychiatric medicine moves beyond symptom management to curative therapies, replacing lifelong treatments with short-term interventions that achieve durable improvements in mental health outcomes.
Mission
Single Dose Therapeutics is dedicated to improving mental health care by developing short-regimen neuroplastogens that enhance psychological resilience. Our mission is to advance these pharmacotherapies through rigorous research and clinical trials, ensuring they become accessible and effective treatment options for psychiatric conditions with unmet needs and those that currently require chronic treatment. We aim to provide innovative therapeutic options that support lasting mental well-being.
In Development
SD-A001 is a drug candidate currently in the preclinical stage of development as a potential pharmacotherapy for conditions characterized by maladaptive learning. It is being evaluated for its ability to promote neuroadaptive processes that modulate homeostatic balance in key neural circuits involved in learning and behavioral regulation. Although SD-A001 has neuroplasticity-enhancing properties, ongoing research suggests it may enable adaptive remodeling of neural networks without inducing psychotomimetic effects. The unique pharmacological profile of SD-A001 offers a novel approach to facilitate extinction of persistent maladaptive associations that can impair emotional, cognitive, and behavioral flexibility.
Single Dose Therapeutics was founded on the premise that innovative solutions to complex medical challenges emerge at the intersection of disciplines, where openness to different perspectives and strong scientific foundations drive the discovery of transformative treatments. My background in pharmaceutics, pharmaceutical engineering, and translational development has shaped a career dedicated to bridging the gap between scientific discovery and real-world medical impact. This philosophy led to the identification of SD-A001, a drug candidate with a unique ability to promote neuroadaptive processes. It offers potential therapeutic value for conditions such as substance use disorders, for which conventional approaches have fallen short. Single Dose Therapeutics is currently a pre-seed startup. The company is laying the groundwork for clinical development of SD-A001 while actively seeking funding and forming strategic partnerships with functional area experts and industry leaders.
Founder's Note
Davin Rautiola
Single Dose Therapeutics
446 Old County Rd, Ste 100-386
Pacifica, CA 94044
650-665-9663